AU2002304814A1 - Protein-protein interactions in adipocytes - Google Patents

Protein-protein interactions in adipocytes

Info

Publication number
AU2002304814A1
AU2002304814A1 AU2002304814A AU2002304814A AU2002304814A1 AU 2002304814 A1 AU2002304814 A1 AU 2002304814A1 AU 2002304814 A AU2002304814 A AU 2002304814A AU 2002304814 A AU2002304814 A AU 2002304814A AU 2002304814 A1 AU2002304814 A1 AU 2002304814A1
Authority
AU
Australia
Prior art keywords
protein
adipocytes
interactions
protein interactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002304814A
Inventor
Laurent Daviet
Pierre Legrain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybrigenics SA
Original Assignee
Hybrigenics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA filed Critical Hybrigenics SA
Publication of AU2002304814A1 publication Critical patent/AU2002304814A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002304814A 2001-03-14 2002-03-14 Protein-protein interactions in adipocytes Abandoned AU2002304814A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27573401P 2001-03-14 2001-03-14
US60/275,734 2001-03-14
PCT/EP2002/003768 WO2002086122A2 (en) 2001-03-14 2002-03-14 Protein-protein interactions in adipocytes

Publications (1)

Publication Number Publication Date
AU2002304814A1 true AU2002304814A1 (en) 2002-11-05

Family

ID=23053586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002304814A Abandoned AU2002304814A1 (en) 2001-03-14 2002-03-14 Protein-protein interactions in adipocytes

Country Status (2)

Country Link
AU (1) AU2002304814A1 (en)
WO (1) WO2002086122A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144493D1 (en) 2000-12-08 2011-06-01 Curagen Corp METHOD FOR THE DETERMINATION AND TREATMENT OF TUBEROUS SCLEROSIS COMPLEX ASSOCIATED DISEASES
US20040072997A1 (en) * 2000-12-20 2004-04-15 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002077019A1 (en) * 2001-03-23 2002-10-03 Dana Farber Cancer Institute,Inc. Methods and compositions for modulating tumor suppression
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
WO2004101607A2 (en) * 2003-05-13 2004-11-25 Hildebrand William H Comparative ligand mapping from mhc class i positive cells
US20050272651A1 (en) * 2004-02-26 2005-12-08 New York University Methods for treating breast cancer using NRIF3 related molecules
WO2006023211A2 (en) * 2004-07-29 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof
WO2006132701A2 (en) 2005-04-04 2006-12-14 Rutgers, The State University Methods and kits for regulation of microtubule assembly and dendrite growth and branching
US8323925B2 (en) 2005-06-17 2012-12-04 Balu Chakravarthy Aβ-binding protein and its peptide derivatives and uses thereof
US8309525B2 (en) 2007-05-30 2012-11-13 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
KR101229819B1 (en) 2009-10-19 2013-02-08 코아스템(주) Compositions for Improving Migration Potential of Stem Cells
US9670259B2 (en) 2013-03-14 2017-06-06 University Of Rochester Method of inhibiting angiogenesis using inhibitors of G-protein-coupled receptor kinase interacting protein-1 (GIT1)
WO2014150350A1 (en) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the linear ubiquitin chain assembly complex (lubac) and related methods
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
GB201601136D0 (en) * 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
WO2018138709A1 (en) 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
EP3917944A1 (en) * 2019-01-28 2021-12-08 Cohbar Inc. Therapeutic peptides
US20220324911A1 (en) * 2019-08-15 2022-10-13 Cohbar, Inc. Therapeutic peptides
WO2021030792A1 (en) * 2019-08-15 2021-02-18 Cohbar, Inc. Therapeutic peptides
US20220324912A1 (en) * 2019-08-15 2022-10-13 Cohbar, Inc. Therapeutic peptides
US20220324909A1 (en) * 2019-08-15 2022-10-13 Cohbar, Inc. Therapeutic peptides
WO2021030799A1 (en) * 2019-08-15 2021-02-18 Cohbar, Inc. Therapeutic peptides
WO2021030794A1 (en) * 2019-08-15 2021-02-18 Cohbar, Inc. Therapeutic peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364772A (en) * 1992-07-20 1994-11-15 Wayne State University DNA molecule encoding the β3 -adrenergic receptor
DE69232486T2 (en) * 1992-12-01 2002-10-31 Centre Nat Rech Scient Intron / exon structure of the genes of the human and mouse beta 3 adrenergic receptors
FR2733513B1 (en) * 1995-04-25 1997-07-18 Centre Nat Rech Scient IMMORTALIZED LINES OF CELLS FROM HUMAN FATTY TISSUE, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
US6187535B1 (en) * 1998-02-18 2001-02-13 Institut Pasteur Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides
EP1002865A1 (en) * 1998-10-30 2000-05-24 Sanofi-Synthelabo Adipose specific protein
AU4652600A (en) * 1999-04-23 2000-11-10 Curagen Corporation Method of identifying ligands for the peroxisome proliferator activated receptorgamma using differential gene expression
WO2002008425A2 (en) * 2000-07-21 2002-01-31 Genaissance Pharmaceuticals, Inc. Haplotypes of the adrb3 gene

Also Published As

Publication number Publication date
WO2002086122A9 (en) 2003-12-18
WO2002086122A3 (en) 2003-10-30
WO2002086122A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
AU2002304814A1 (en) Protein-protein interactions in adipocytes
AU2002240892A1 (en) Protein-protein interactions in adipocyte cells
AU2002343025A1 (en) Improvements in footwear
AUPS198302A0 (en) Improvements in bowsprits
AU2002301354A1 (en) Improvements in Transmissometers
AU2002301358A1 (en) Improvements in Transmissometers
AU2001272655A1 (en) Improvements in valves
AU2002302851A1 (en) Atopy
AU2003228355A1 (en) Adipocytes and uses thereof
AU2002248299A1 (en) Protein-protein interactions
AU2002230895A1 (en) Protein-protein interactions
AU2002245214A1 (en) Protein-protein interactions
AU2001268621A1 (en) Protein-protein interactions
AU2001263325A1 (en) Protein-protein interactions
AU2002236645A1 (en) Protein-protein interactions
AU2002249808A1 (en) Protein-protein interactions
AU2002230728A1 (en) Protein-protein interactions
AU2002331435A1 (en) Construction methods in space
AUPR473801A0 (en) Improvements in components
AU2002343038A1 (en) Improvements in keyboards
AUPR808601A0 (en) Improvements in levels
AU2002238704A1 (en) Improvements in insulating materials
AUPR889301A0 (en) Improvements in cylinders
AU2002253805A1 (en) Protein-protein interactions
AU2002245135A1 (en) Protein-protein interactions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase